The Valley Desk

NCT02454842 · Interventional trial

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Overall registry status Terminated

Phase 2

Conditions NSCLC, Non-small Cell Lung Cancer, Non-squamous NSCLC

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov